Search

Objectives: This study aims to quantitatively assess the profile of the choroidal thickness (ChT) in patients with ankylosing spondylitis (AS) using optical coherence tomography (OCT), and to examine whether the posterior eye segment abnormalities in active AS patients are reversible by infliximab therapy. Patients and methods: Thirty-one patients with AS (22 males, 9 females; mean age: 39.6±12.3 years; range, 22 to 68 years) and 24 healthy controls (16 males, 8 females; mean age: 40.8±8.9 years; range, 35 to 61 years) were enrolled between October 2014 and March 2016. Patients' clinical and demographic characteristics were recorded. Using OCT, we performed retinal nerve fiber layer (RNFL) thickness, ganglion cell complex, and ChT measurements in AS patients before and six months after the initiation of infliximab therapy, and in healthy controls. Results: At baseline, patients with AS had higher ChT (mean±standard deviation: 347.5±114.4 µm) compared to healthy controls (322.1±62.8 µm), although this did not reach statistical significance level (p=0.283). At six months after the first measurement, the mean ChT was significantly decreased (under infliximab therapy: 326.5±99.7 µm vs. before: 347.5±114.4 µm, p=0.018) in AS group, while no significant change was observed in the control group (p=0.102). RNFL thickness in the AS group was significantly decreased after six months of treatment with infliximab (p=0.008). Conclusion: By evaluating the posterior eye segment of patients with AS using OCT, this study has demonstrated that active AS patients had higher ChT. The significant reduction in this ChT after infliximab therapy may be mediating the established effective suppressing action of infliximab on uveitis attacks. [ABSTRACT FROM AUTHOR]

Copyright of Turkish Journal of Trauma & Emergency Surgery / Ulusal Travma ve Acil Cerrahi Dergisi is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Purpose. To assess the repeatability and reproducibility of ocular biometry and intraocular lens (IOL) power measurements obtained by ophthalmology residents using an AL-Scan device, a novel optical biometer. Methods. Two ophthalmology residents were instructed regarding the AL-Scan device. Both performed ocular biometry and IOL power measurements using AL-Scan, three times on each of 128 eyes, independently of one another. Corneal keratometry readings, horizontal iris width, central corneal thickness, anterior chamber depth, pupil size, and axial length values measured by both residents were recorded together with IOL power values calculated on the basis of four different IOL calculation formulas (SRK/T, Holladay, and HofferQ). Repeatability and reproducibility of the measurements obtained were analyzed using the intraclass correlation coefficient (ICC). Results. Repeatability (ICC, 0.872-0.999 for resident 1 versus 0.905-0.999 for resident 2) and reproducibility (ICC, 0.916-0.999) were high for all biometric measurements. Repeatability (ICC, 0.981-0.983 for resident 1 versus 0.995-0.996 for resident 2) and reproducibility were also high for all IOL power measurements (ICC, 0.996 for all). Conclusions. The AL-Scan device exhibits good repeatability and reproducibility in all biometric measurements and IOL power calculations, independent of the operator concerned. [ABSTRACT FROM AUTHOR]

To investigate changes of tear osmolarity in patients with Graves ophthalmopathy (GO). Twenty-three patients with GO (GO group) and 25 healthy controls (control group) were enrolled in the study. GO patients were divided into two subgroups as active GO and inactive GO subgroups. Orbital inflammatory activity was evaluated using the clinical activity score (CAS). Tear osmolarity was measured using TearLab Osmolarity System (TearLab™ Corp., San Diego, CA). The GO patients had significantly higher tear osmolarity levels than the healthy controls (p<0.001). Tear osmolarity levels were significantly higher in active GO subgroup than in inactive GO subgroup (p=0.003). We have revealed that GO patients had significantly higher tear osmolarity levels than healthy controls. In addition, there was a relationship between the disease activity and tear osmolarity. Therefore, we suggest that tear osmolarity measurement may be added to other tests for diagnosing dry eye severity in GO and it may be useful to evaluate the disease activity in patients with GO. [ABSTRACT FROM AUTHOR]